Pandemic seen weighing on Eylea as Regeneron reports consensus-beating quarter, positive PD-1 data

A predicted downturn in new Eylea patients due to COVID-19 didn’t dampen shares of Regeneron Tuesday as the company reported a consensus-beating quarter and positive data for its PD-1 inhibitor.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) added $32.55 to $574.37 Tuesday, gaining about $3.7 billion in market cap. ...